TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Data presented at AASLD Liver Meeting 2017
Strasbourg, October 23, 2017- 7:30 am - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that the analyses conducted on patients with chronic hepatitis B receiving standard antiviral therapies and a single dose of TG1050 in the Phase 1/1b trial, confirm the good tolerability profile and demonstrate the immunogenicity of this novel therapeutic vaccine.
Transgene presented a poster describing the first promising clinical data of TG1050 on October 21, 2017, at the annual meeting of the AASLD (American Association for the Study of Liver Diseases) that is currently taking place in Washington, DC.
These results were obtained from the first cohort of patients included in the Phase 1/1b trial; patients that are currently treated with standard antiviral therapy also received a single dose of TG1050. The data presented further strengthen the first elements communicated in 2016 , i.e. a very satisfying tolerability profile of TG1050. They also confirm the product’s mechanism of action.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer